A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas
Sponsor: Ipsen
A PHASE3 clinical study on Metastatic Adenocarcinoma of the Pancreas, this trial is completed. The trial is conducted by Ipsen and has accumulated 36 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
36 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Mar 2026 [monthly]
Completed PHASE3
-
Mar 2025 — Sep 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 31 earlier versions
-
Oct 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
-
Nov 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Aug 2020 — Oct 2020 [monthly]
Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE3
-
May 2020 — Jul 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE3
-
Feb 2020 — Apr 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalst, Belgium , Alicante, Spain , Asheville, United States , Athens, Greece , Austin, United States , Badajoz, Spain , Badalona, Spain , Bakersfield, United States , Bankstown, Australia , Barcelona, Spain and 156 more locations